|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61P 35/00 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/519 | (2006.01) | ||
| A61P 37/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) |
| (11) | Number of the document | 3150256 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16185090.4 |
| Date of filing the European patent application | 2013-11-01 | |
| (97) | Date of publication of the European application | 2017-04-05 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-15 |
| (46) | Date of publication of the claims translation | 2020-11-10 |
| (30) | Number | Date | Country code |
| 4595CH2012 | 2012-11-02 | IN | |
| 201361771812 P | 2013-03-02 | US |
| (72) |
Weiss, Michael, US
Miskin, Hari, US
Sportelli, Peter, US
Vakkalanka, Swaroop K.V.S, CH
|
| (73) |
Rhizen Pharmaceuticals S.A.,
Fritz Courvoisier 40, 2300 La Chaux de Fonds,
CH
Laboratoire Franēais du Fractionnement et des Biotechnologies, 3, avenue des Tropiques, ZA Courtaboeuf,, 91940 Les Ulis, FR TG Therapeutics Inc., 2 Gransevoort Street, 9th Floor, New York, NY 10014, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-CD20 antikūno ir PI3 kinazės selektyvaus inhibitoriaus derinys |
| COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR |
| Payment date | Validity (years) | Amount | |
| 2021-10-28 | 9 | 208.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2022-11-01 |